Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.